NO321058B1 - Anvendelse av 2-aminobenzoksazinonderivater ved fremstilling av et medikament for profylakse eller behandling av overvekt eller en overvektsrelatert forstyrrelse, 2-aminobenzoksazinonderivater, fremgangsmate for fremstilling derav, farmasoytiske preparater og matprodukter som inneholder derivatene, anvendelser av derivatene samt kosmetisk fremgangsmate ved administrering derav. - Google Patents
Anvendelse av 2-aminobenzoksazinonderivater ved fremstilling av et medikament for profylakse eller behandling av overvekt eller en overvektsrelatert forstyrrelse, 2-aminobenzoksazinonderivater, fremgangsmate for fremstilling derav, farmasoytiske preparater og matprodukter som inneholder derivatene, anvendelser av derivatene samt kosmetisk fremgangsmate ved administrering derav. Download PDFInfo
- Publication number
- NO321058B1 NO321058B1 NO20013380A NO20013380A NO321058B1 NO 321058 B1 NO321058 B1 NO 321058B1 NO 20013380 A NO20013380 A NO 20013380A NO 20013380 A NO20013380 A NO 20013380A NO 321058 B1 NO321058 B1 NO 321058B1
- Authority
- NO
- Norway
- Prior art keywords
- benzoxazin
- alkyl
- heteroaryl
- aryl
- phenylamino
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 43
- 208000008589 Obesity Diseases 0.000 title claims description 30
- 235000020824 obesity Nutrition 0.000 title claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 238000011282 treatment Methods 0.000 title claims description 21
- 239000003814 drug Substances 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 239000002537 cosmetic Substances 0.000 title claims description 10
- 235000013305 food Nutrition 0.000 title claims description 9
- 230000008569 process Effects 0.000 title claims description 7
- 238000011321 prophylaxis Methods 0.000 title claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 33
- 206010033307 Overweight Diseases 0.000 title description 2
- MCDXWLAYOXBQBG-UHFFFAOYSA-N 2-amino-4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2CC(=O)N(N)OC2=C1 MCDXWLAYOXBQBG-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims description 119
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 230000002829 reductive effect Effects 0.000 claims description 57
- 125000001072 heteroaryl group Chemical group 0.000 claims description 55
- 239000001257 hydrogen Substances 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 125000004432 carbon atom Chemical group C* 0.000 claims description 29
- -1 hydroxy, amino Chemical group 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 18
- 150000001408 amides Chemical class 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 230000004580 weight loss Effects 0.000 claims description 14
- 102000004882 Lipase Human genes 0.000 claims description 13
- 108090001060 Lipase Proteins 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 239000004367 Lipase Substances 0.000 claims description 11
- 235000019421 lipase Nutrition 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 8
- 125000004185 ester group Chemical group 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 238000007363 ring formation reaction Methods 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 125000005418 aryl aryl group Chemical group 0.000 claims description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- WHEKXHXYMRSBOW-UHFFFAOYSA-N 6-methyl-2-(4-phenoxyanilino)-3,1-benzoxazin-4-one Chemical compound O1C(=O)C2=CC(C)=CC=C2N=C1NC(C=C1)=CC=C1OC1=CC=CC=C1 WHEKXHXYMRSBOW-UHFFFAOYSA-N 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- OGKPWJCQRPMWFU-UHFFFAOYSA-N butyl 4-[(6-methyl-4-oxo-3,1-benzoxazin-2-yl)amino]benzoate Chemical compound C1=CC(C(=O)OCCCC)=CC=C1NC1=NC2=CC=C(C)C=C2C(=O)O1 OGKPWJCQRPMWFU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- SRPVIUOVOOFGQQ-UHFFFAOYSA-N 2-(4-benzoylanilino)-7-methyl-3,1-benzoxazin-4-one Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC(C=C1)=CC=C1C(=O)C1=CC=CC=C1 SRPVIUOVOOFGQQ-UHFFFAOYSA-N 0.000 claims description 2
- KPJKYZYRHCKOAQ-UHFFFAOYSA-N 2-(4-hexylanilino)-6-methyl-3,1-benzoxazin-4-one Chemical compound C1=CC(CCCCCC)=CC=C1NC1=NC2=CC=C(C)C=C2C(=O)O1 KPJKYZYRHCKOAQ-UHFFFAOYSA-N 0.000 claims description 2
- HKFRGWMWWWWFHQ-UHFFFAOYSA-N 2-(4-phenoxyanilino)-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 HKFRGWMWWWWFHQ-UHFFFAOYSA-N 0.000 claims description 2
- VAKQOMDNWGTHHR-UHFFFAOYSA-N 2-(4-phenoxyanilino)-7-(trifluoromethyl)-3,1-benzoxazin-4-one Chemical compound C=1C(C(F)(F)F)=CC=C(C(O2)=O)C=1N=C2NC(C=C1)=CC=C1OC1=CC=CC=C1 VAKQOMDNWGTHHR-UHFFFAOYSA-N 0.000 claims description 2
- LFNRYAMNRIQETP-UHFFFAOYSA-N 2-anilino-7-octyl-3,1-benzoxazin-4-one Chemical compound C=1C(CCCCCCCC)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 LFNRYAMNRIQETP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 claims description 2
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- VICOSHKERFIQPS-UHFFFAOYSA-N 2-anilino-4-oxo-3,1-benzoxazine-6-carbonitrile Chemical compound N=1C2=CC=C(C#N)C=C2C(=O)OC=1NC1=CC=CC=C1 VICOSHKERFIQPS-UHFFFAOYSA-N 0.000 claims 2
- IHVXUPNINOXABX-UHFFFAOYSA-N 2-anilino-7-ethyl-3,1-benzoxazin-4-one Chemical compound C=1C(CC)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 IHVXUPNINOXABX-UHFFFAOYSA-N 0.000 claims 2
- ILUIOUOLLQEVNH-UHFFFAOYSA-N 2-(1h-pyrrol-3-ylamino)-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC=1C=CNC=1 ILUIOUOLLQEVNH-UHFFFAOYSA-N 0.000 claims 1
- PRFHHLQOTVIPMG-UHFFFAOYSA-N 2-(2-phenoxyanilino)-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC1=CC=CC=C1OC1=CC=CC=C1 PRFHHLQOTVIPMG-UHFFFAOYSA-N 0.000 claims 1
- CKYXUGFIOMLLTI-UHFFFAOYSA-N 2-(3-phenoxyanilino)-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC(C=1)=CC=CC=1OC1=CC=CC=C1 CKYXUGFIOMLLTI-UHFFFAOYSA-N 0.000 claims 1
- HFXFOJRTNOZZRG-UHFFFAOYSA-N 2-(4-aminoanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(N)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 HFXFOJRTNOZZRG-UHFFFAOYSA-N 0.000 claims 1
- SSIOHCZFLKTZMU-UHFFFAOYSA-N 2-(4-butylanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(CCCC)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 SSIOHCZFLKTZMU-UHFFFAOYSA-N 0.000 claims 1
- QBHHRJRBHXDCMO-UHFFFAOYSA-N 2-(4-chloroanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(Cl)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 QBHHRJRBHXDCMO-UHFFFAOYSA-N 0.000 claims 1
- LDRACLGWMZWSGF-UHFFFAOYSA-N 2-(4-heptoxyanilino)-6-methyl-3,1-benzoxazin-4-one Chemical compound C1=CC(OCCCCCCC)=CC=C1NC1=NC2=CC=C(C)C=C2C(=O)O1 LDRACLGWMZWSGF-UHFFFAOYSA-N 0.000 claims 1
- QEHNWSOKTOFQMT-UHFFFAOYSA-N 2-(4-hydroxyanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(O)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 QEHNWSOKTOFQMT-UHFFFAOYSA-N 0.000 claims 1
- UHVKKDSXQJGPDB-UHFFFAOYSA-N 2-(4-methoxyanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(OC)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 UHVKKDSXQJGPDB-UHFFFAOYSA-N 0.000 claims 1
- ISKKMQHVYDPWPV-UHFFFAOYSA-N 2-(4-methylanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(C)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 ISKKMQHVYDPWPV-UHFFFAOYSA-N 0.000 claims 1
- ZULSAVVHRIQZTI-UHFFFAOYSA-N 2-(4-propan-2-ylanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(C(C)C)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 ZULSAVVHRIQZTI-UHFFFAOYSA-N 0.000 claims 1
- QRGKQGPQDLRKDU-UHFFFAOYSA-N 2-(6-phenylhexylamino)-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NCCCCCCC1=CC=CC=C1 QRGKQGPQDLRKDU-UHFFFAOYSA-N 0.000 claims 1
- KRZHQYKKBPTALV-UHFFFAOYSA-N 2-(cyclopropylamino)-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC1CC1 KRZHQYKKBPTALV-UHFFFAOYSA-N 0.000 claims 1
- UZCBPGZCSFBLLA-UHFFFAOYSA-N 2-(dodec-7-ynylamino)-6-methyl-3,1-benzoxazin-4-one Chemical compound C1=C(C)C=C2C(=O)OC(NCCCCCCC#CCCCC)=NC2=C1 UZCBPGZCSFBLLA-UHFFFAOYSA-N 0.000 claims 1
- LVKYVTCQSYNTBW-UHFFFAOYSA-N 2-(hexadecylamino)-6-methyl-3,1-benzoxazin-4-one Chemical compound C1=C(C)C=C2C(=O)OC(NCCCCCCCCCCCCCCCC)=NC2=C1 LVKYVTCQSYNTBW-UHFFFAOYSA-N 0.000 claims 1
- DURPUFUTUNPYHX-UHFFFAOYSA-N 2-(naphthalen-2-ylamino)-3,1-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)OC(NC=3C=C4C=CC=CC4=CC=3)=NC2=C1 DURPUFUTUNPYHX-UHFFFAOYSA-N 0.000 claims 1
- MYBXTXQHOCBQCU-UHFFFAOYSA-N 2-(piperidin-4-ylamino)-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC1CCNCC1 MYBXTXQHOCBQCU-UHFFFAOYSA-N 0.000 claims 1
- AXYNLDHGDPTNLK-UHFFFAOYSA-N 2-[(7-methyl-4-oxo-3,1-benzoxazin-2-yl)amino]benzonitrile Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1C#N AXYNLDHGDPTNLK-UHFFFAOYSA-N 0.000 claims 1
- NCFWNAGDFTUTSR-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3,1-benzoxazin-4-one Chemical compound FC(F)(F)C1=CC=CC(NC=2OC(=O)C3=CC=CC=C3N=2)=C1 NCFWNAGDFTUTSR-UHFFFAOYSA-N 0.000 claims 1
- PALJIWYZTFQCRC-UHFFFAOYSA-N 2-[4-(trifluoromethyl)anilino]-3,1-benzoxazin-4-one Chemical compound C1=CC(C(F)(F)F)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 PALJIWYZTFQCRC-UHFFFAOYSA-N 0.000 claims 1
- YWXZWFMDIOEGTG-UHFFFAOYSA-N 2-[6-(1h-pyrrol-2-yl)hexylamino]-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NCCCCCCC1=CC=CN1 YWXZWFMDIOEGTG-UHFFFAOYSA-N 0.000 claims 1
- UUMLXNZZKFQMMR-UHFFFAOYSA-N 2-anilino-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC1=CC=CC=C1 UUMLXNZZKFQMMR-UHFFFAOYSA-N 0.000 claims 1
- HOKWWRBMVSPSLT-UHFFFAOYSA-N 2-anilino-4-oxo-3,1-benzoxazine-6-carbaldehyde Chemical compound O1C(=O)C2=CC(C=O)=CC=C2N=C1NC1=CC=CC=C1 HOKWWRBMVSPSLT-UHFFFAOYSA-N 0.000 claims 1
- USVUSBRRPAMJGT-UHFFFAOYSA-N 2-anilino-4-oxo-3,1-benzoxazine-6-sulfinic acid Chemical compound O1C(=O)C2=CC(S(=O)O)=CC=C2N=C1NC1=CC=CC=C1 USVUSBRRPAMJGT-UHFFFAOYSA-N 0.000 claims 1
- IITVJIVEURYYRL-UHFFFAOYSA-N 2-anilino-5-fluoro-3,1-benzoxazin-4-one Chemical compound O1C(=O)C=2C(F)=CC=CC=2N=C1NC1=CC=CC=C1 IITVJIVEURYYRL-UHFFFAOYSA-N 0.000 claims 1
- YBFOWPXXISBBCK-UHFFFAOYSA-N 2-anilino-6,7-dimethyl-3,1-benzoxazin-4-one Chemical compound O1C(=O)C=2C=C(C)C(C)=CC=2N=C1NC1=CC=CC=C1 YBFOWPXXISBBCK-UHFFFAOYSA-N 0.000 claims 1
- QXUNQIOOTBDRQD-UHFFFAOYSA-N 2-anilino-6-(trifluoromethyl)-3,1-benzoxazin-4-one Chemical compound O1C(=O)C2=CC(C(F)(F)F)=CC=C2N=C1NC1=CC=CC=C1 QXUNQIOOTBDRQD-UHFFFAOYSA-N 0.000 claims 1
- ZDOKDIMOAKOXNC-UHFFFAOYSA-N 2-anilino-6-chloro-3,1-benzoxazin-4-one Chemical compound O1C(=O)C2=CC(Cl)=CC=C2N=C1NC1=CC=CC=C1 ZDOKDIMOAKOXNC-UHFFFAOYSA-N 0.000 claims 1
- CFHSAEUDMPOUPY-UHFFFAOYSA-N 2-anilino-6-cyclopropyl-3,1-benzoxazin-4-one Chemical compound N=1C2=CC=C(C3CC3)C=C2C(=O)OC=1NC1=CC=CC=C1 CFHSAEUDMPOUPY-UHFFFAOYSA-N 0.000 claims 1
- WAHWHYZPYHLYTG-UHFFFAOYSA-N 2-anilino-6-methyl-3,1-benzoxazin-4-one Chemical compound O1C(=O)C2=CC(C)=CC=C2N=C1NC1=CC=CC=C1 WAHWHYZPYHLYTG-UHFFFAOYSA-N 0.000 claims 1
- RTEHSNJXVDNBKZ-UHFFFAOYSA-N 2-anilino-6-nitro-3,1-benzoxazin-4-one Chemical compound O1C(=O)C2=CC([N+](=O)[O-])=CC=C2N=C1NC1=CC=CC=C1 RTEHSNJXVDNBKZ-UHFFFAOYSA-N 0.000 claims 1
- SHHCAUQRFUKFOP-UHFFFAOYSA-N 2-anilino-6-sulfanyl-3,1-benzoxazin-4-one Chemical compound O1C(=O)C2=CC(S)=CC=C2N=C1NC1=CC=CC=C1 SHHCAUQRFUKFOP-UHFFFAOYSA-N 0.000 claims 1
- KCTKJSZBMOZLGZ-UHFFFAOYSA-N 2-anilino-7-(trifluoromethyl)-3,1-benzoxazin-4-one Chemical compound C=1C(C(F)(F)F)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 KCTKJSZBMOZLGZ-UHFFFAOYSA-N 0.000 claims 1
- WQVVOBIFVHKGNN-UHFFFAOYSA-N 2-anilino-7-butyl-3,1-benzoxazin-4-one Chemical compound C=1C(CCCC)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 WQVVOBIFVHKGNN-UHFFFAOYSA-N 0.000 claims 1
- CQDBIBPUERIOBM-UHFFFAOYSA-N 2-anilino-7-cyclopropyl-3,1-benzoxazin-4-one Chemical compound N=1C2=CC(C3CC3)=CC=C2C(=O)OC=1NC1=CC=CC=C1 CQDBIBPUERIOBM-UHFFFAOYSA-N 0.000 claims 1
- XKVAALZMJMWQNN-UHFFFAOYSA-N 2-anilino-7-fluoro-3,1-benzoxazin-4-one Chemical compound C=1C(F)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 XKVAALZMJMWQNN-UHFFFAOYSA-N 0.000 claims 1
- FXHDRTZNZVJHBR-UHFFFAOYSA-N 2-anilino-7-hydroxy-3,1-benzoxazin-4-one Chemical compound C=1C(O)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 FXHDRTZNZVJHBR-UHFFFAOYSA-N 0.000 claims 1
- ZXZWPIVFCQULBR-UHFFFAOYSA-N 2-anilino-7-methyl-3,1-benzoxazin-4-one Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 ZXZWPIVFCQULBR-UHFFFAOYSA-N 0.000 claims 1
- SAJWWOJXDQKTLF-UHFFFAOYSA-N 2-anilino-8-fluoro-3,1-benzoxazin-4-one Chemical compound FC1=CC=CC(C(O2)=O)=C1N=C2NC1=CC=CC=C1 SAJWWOJXDQKTLF-UHFFFAOYSA-N 0.000 claims 1
- IBDJYZFNKDWXDM-UHFFFAOYSA-N 2-anilinopyrido[2,3-d][1,3]oxazin-4-one Chemical compound N=1C2=NC=CC=C2C(=O)OC=1NC1=CC=CC=C1 IBDJYZFNKDWXDM-UHFFFAOYSA-N 0.000 claims 1
- MRZMCPJITHGRLA-UHFFFAOYSA-N 2-anilinopyrido[3,4-d][1,3]oxazin-4-one Chemical compound N=1C2=CN=CC=C2C(=O)OC=1NC1=CC=CC=C1 MRZMCPJITHGRLA-UHFFFAOYSA-N 0.000 claims 1
- WPWUMZKCYISKMC-UHFFFAOYSA-N 3-[(7-methyl-4-oxo-3,1-benzoxazin-2-yl)amino]benzonitrile Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC(C#N)=C1 WPWUMZKCYISKMC-UHFFFAOYSA-N 0.000 claims 1
- LQBGBFWFTWJVMR-UHFFFAOYSA-N 4-[(4-oxo-3,1-benzoxazin-2-yl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 LQBGBFWFTWJVMR-UHFFFAOYSA-N 0.000 claims 1
- XBZOEFOBAZHKHZ-UHFFFAOYSA-N 4-[(4-oxo-3,1-benzoxazin-2-yl)amino]benzonitrile Chemical compound N=1C2=CC=CC=C2C(=O)OC=1NC1=CC=C(C#N)C=C1 XBZOEFOBAZHKHZ-UHFFFAOYSA-N 0.000 claims 1
- ZNVZMQOFFJWFIW-UHFFFAOYSA-N 4-[(7-methyl-4-oxo-3,1-benzoxazin-2-yl)amino]benzonitrile Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC1=CC=C(C#N)C=C1 ZNVZMQOFFJWFIW-UHFFFAOYSA-N 0.000 claims 1
- IZOLPXHXHCWDKH-UHFFFAOYSA-N 6-iodo-2-(octylamino)-3,1-benzoxazin-4-one Chemical compound C1=C(I)C=C2C(=O)OC(NCCCCCCCC)=NC2=C1 IZOLPXHXHCWDKH-UHFFFAOYSA-N 0.000 claims 1
- ZSZQPTPLWHGWKY-UHFFFAOYSA-N 6-methyl-2-(6-thiophen-2-ylhexylamino)-3,1-benzoxazin-4-one Chemical compound O1C(=O)C2=CC(C)=CC=C2N=C1NCCCCCCC1=CC=CS1 ZSZQPTPLWHGWKY-UHFFFAOYSA-N 0.000 claims 1
- MUDRAEKRQDHCDK-UHFFFAOYSA-N 6-methyl-2-(naphthalen-2-ylamino)-3,1-benzoxazin-4-one Chemical compound C1=CC=CC2=CC(NC3=NC4=CC=C(C=C4C(=O)O3)C)=CC=C21 MUDRAEKRQDHCDK-UHFFFAOYSA-N 0.000 claims 1
- JZQCLPGGDXXIOM-UHFFFAOYSA-N 7-amino-2-anilino-3,1-benzoxazin-4-one Chemical compound C=1C(N)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1 JZQCLPGGDXXIOM-UHFFFAOYSA-N 0.000 claims 1
- BIIHQRAKMPLRGH-UHFFFAOYSA-N 7-butyl-2-(octylamino)-3,1-benzoxazin-4-one Chemical compound CCCCC1=CC=C2C(=O)OC(NCCCCCCCC)=NC2=C1 BIIHQRAKMPLRGH-UHFFFAOYSA-N 0.000 claims 1
- GLFFSBXVUSFGBP-UHFFFAOYSA-N 7-methyl-2-(2-phenoxyanilino)-3,1-benzoxazin-4-one Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC1=CC=CC=C1OC1=CC=CC=C1 GLFFSBXVUSFGBP-UHFFFAOYSA-N 0.000 claims 1
- BDEDNRAOKYDITQ-UHFFFAOYSA-N 7-methyl-2-(3-phenoxyanilino)-3,1-benzoxazin-4-one Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC(C=1)=CC=CC=1OC1=CC=CC=C1 BDEDNRAOKYDITQ-UHFFFAOYSA-N 0.000 claims 1
- PKSPNUSISUVHGC-UHFFFAOYSA-N 7-methyl-2-(4-octylanilino)-3,1-benzoxazin-4-one Chemical compound C1=CC(CCCCCCCC)=CC=C1NC1=NC2=CC(C)=CC=C2C(=O)O1 PKSPNUSISUVHGC-UHFFFAOYSA-N 0.000 claims 1
- RVVZOERBGTUAIP-UHFFFAOYSA-N ethyl 4-[(4-oxo-3,1-benzoxazin-2-yl)amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC1=NC2=CC=CC=C2C(=O)O1 RVVZOERBGTUAIP-UHFFFAOYSA-N 0.000 claims 1
- FNDSACBEELZRQG-UHFFFAOYSA-N n-(2-anilino-4-oxo-3,1-benzoxazin-6-yl)acetamide Chemical compound O1C(=O)C2=CC(NC(=O)C)=CC=C2N=C1NC1=CC=CC=C1 FNDSACBEELZRQG-UHFFFAOYSA-N 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- 229940088598 enzyme Drugs 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 10
- 102000019280 Pancreatic lipases Human genes 0.000 description 10
- 108050006759 Pancreatic lipases Proteins 0.000 description 10
- 239000003925 fat Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 229940116369 pancreatic lipase Drugs 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229940040461 lipase Drugs 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000019577 caloric intake Nutrition 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000006798 ring closing metathesis reaction Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- PNBUGOFIKAHZRW-UHFFFAOYSA-N 1-isocyanato-4-phenoxybenzene Chemical class C1=CC(N=C=O)=CC=C1OC1=CC=CC=C1 PNBUGOFIKAHZRW-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 235000001258 Cinchona calisaya Nutrition 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229960000948 quinine Drugs 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- YYPXNAAEYOJYES-UHFFFAOYSA-N 2-amino-3,1-benzoxazin-4-one Chemical class C1=CC=C2C(=O)OC(N)=NC2=C1 YYPXNAAEYOJYES-UHFFFAOYSA-N 0.000 description 2
- NBUUUJWWOARGNW-UHFFFAOYSA-N 2-amino-5-methylbenzoic acid Chemical compound CC1=CC=C(N)C(C(O)=O)=C1 NBUUUJWWOARGNW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 2
- 229910000071 diazene Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000276 sedentary effect Effects 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- UUUAWYNSKSCNMD-UHFFFAOYSA-N (4-isocyanatophenyl)-phenylmethanone Chemical compound C1=CC(N=C=O)=CC=C1C(=O)C1=CC=CC=C1 UUUAWYNSKSCNMD-UHFFFAOYSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- AWHAUPZHZYUHOM-UHFFFAOYSA-N 1,2-dibutyrin Chemical compound CCCC(=O)OCC(CO)OC(=O)CCC AWHAUPZHZYUHOM-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- OOZQSVXPBCINJF-UHFFFAOYSA-N 1-bromo-4-octylbenzene Chemical compound CCCCCCCCC1=CC=C(Br)C=C1 OOZQSVXPBCINJF-UHFFFAOYSA-N 0.000 description 1
- HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 1
- ZOSTXKYJDXPWKN-UHFFFAOYSA-N 1-isocyanato-4-octylbenzene Chemical compound CCCCCCCCC1=CC=C(N=C=O)C=C1 ZOSTXKYJDXPWKN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VRRIKQMIAFHSNY-UHFFFAOYSA-N 2-amino-1,3-benzoxazin-4-one Chemical class C1=CC=C2OC(N)=NC(=O)C2=C1 VRRIKQMIAFHSNY-UHFFFAOYSA-N 0.000 description 1
- RPGKFFKUTVJVPY-UHFFFAOYSA-N 2-amino-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1 RPGKFFKUTVJVPY-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- ORKQJTBYQZITLA-UHFFFAOYSA-N 4-octylaniline Chemical compound CCCCCCCCC1=CC=C(N)C=C1 ORKQJTBYQZITLA-UHFFFAOYSA-N 0.000 description 1
- VHJKLJMPBCXLKB-UHFFFAOYSA-N 7-methyl-2-(4-phenoxyanilino)-3,1-benzoxazin-4-one Chemical compound C=1C(C)=CC=C(C(O2)=O)C=1N=C2NC(C=C1)=CC=C1OC1=CC=CC=C1 VHJKLJMPBCXLKB-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- PPALAXNUBRCWAO-UHFFFAOYSA-N C(CCCCCCC)C1=CC(=C(C(=O)O)C=C1)N.C(CCCCCCC)C=1C=C(C(C(=O)O)=CC1)N Chemical compound C(CCCCCCC)C1=CC(=C(C(=O)O)C=C1)N.C(CCCCCCC)C=1C=C(C(C(=O)O)=CC1)N PPALAXNUBRCWAO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 101001134456 Homo sapiens Pancreatic triacylglycerol lipase Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102000017055 Lipoprotein Lipase Human genes 0.000 description 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 1
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 101150020251 NR13 gene Proteins 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102000006831 Protein phosphatase 2C Human genes 0.000 description 1
- 108010047313 Protein phosphatase 2C Proteins 0.000 description 1
- 101001064310 Rattus norvegicus Gastric triacylglycerol lipase Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000005840 aryl radicals Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000003180 beta-lactone group Chemical group 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000046759 human PNLIP Human genes 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000010893 paper waste Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical class O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108010045122 retinyl esterase Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9900416.0A GB9900416D0 (en) | 1999-01-08 | 1999-01-08 | Inhibitors |
| PCT/GB2000/000031 WO2000040569A1 (en) | 1999-01-08 | 2000-01-06 | 2-amino-benzoxazinone derivatives for the treatment of obesity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013380D0 NO20013380D0 (no) | 2001-07-06 |
| NO20013380L NO20013380L (no) | 2001-09-07 |
| NO321058B1 true NO321058B1 (no) | 2006-03-06 |
Family
ID=10845777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013380A NO321058B1 (no) | 1999-01-08 | 2001-07-06 | Anvendelse av 2-aminobenzoksazinonderivater ved fremstilling av et medikament for profylakse eller behandling av overvekt eller en overvektsrelatert forstyrrelse, 2-aminobenzoksazinonderivater, fremgangsmate for fremstilling derav, farmasoytiske preparater og matprodukter som inneholder derivatene, anvendelser av derivatene samt kosmetisk fremgangsmate ved administrering derav. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6656934B2 (zh) |
| EP (1) | EP1144395B1 (zh) |
| JP (1) | JP2002534419A (zh) |
| KR (1) | KR100615914B1 (zh) |
| CN (1) | CN100480245C (zh) |
| AR (1) | AR022203A1 (zh) |
| AT (1) | ATE293610T1 (zh) |
| AU (1) | AU770342B2 (zh) |
| CA (1) | CA2359987C (zh) |
| DE (1) | DE60019556T2 (zh) |
| DK (1) | DK1144395T3 (zh) |
| ES (1) | ES2240051T3 (zh) |
| GB (1) | GB9900416D0 (zh) |
| HK (1) | HK1047284A1 (zh) |
| HU (1) | HUP0104909A3 (zh) |
| MY (1) | MY129247A (zh) |
| NO (1) | NO321058B1 (zh) |
| NZ (1) | NZ512739A (zh) |
| PL (1) | PL350412A1 (zh) |
| PT (1) | PT1144395E (zh) |
| RU (1) | RU2244711C2 (zh) |
| WO (1) | WO2000040569A1 (zh) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9900416D0 (en) * | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| CA2286451A1 (en) | 1999-10-14 | 2001-04-14 | Grant A. Mitchell | Hormone-sensitive lipase mediated male infertility |
| GB0001572D0 (en) * | 2000-01-24 | 2000-03-15 | Alizyme Therapeutics Ltd | Inhibitors |
| CZ301813B6 (cs) | 2000-06-27 | 2010-06-30 | F. Hoffmann-La Roche Ag | Zpusob prípravy farmaceutické kompozice |
| ES2240516T3 (es) | 2000-07-28 | 2005-10-16 | F. Hoffmann-La Roche Ag | Nuevo uso de los inhibidores de lipasa. |
| PL204443B1 (pl) | 2000-07-28 | 2010-01-29 | Hoffmann La Roche | Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe |
| US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
| US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| DE10135027A1 (de) * | 2001-07-18 | 2003-02-06 | Solvay Pharm Gmbh | Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen |
| EP1578987A2 (en) | 2001-08-03 | 2005-09-28 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
| US6943001B2 (en) | 2001-08-03 | 2005-09-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
| PL366851A1 (en) | 2001-08-22 | 2005-02-07 | Aventis Pharma Deutschland Gmbh | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof |
| PL368994A1 (en) * | 2001-08-30 | 2005-04-04 | Alizyme Therapeutics Limited | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |
| US6884812B2 (en) | 2001-08-31 | 2005-04-26 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals |
| PT1425014E (pt) | 2001-08-31 | 2007-03-30 | Sanofi Aventis Deutschland | Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar |
| US7399777B2 (en) | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
| EP1467978A4 (en) * | 2001-12-20 | 2005-11-02 | Osi Pharm Inc | "COMPOUNDS THAT CONTAIN VACCINATES DRUG LIPASE, THEIR SYNTHESIS AND USE" |
| US7078404B2 (en) | 2002-04-11 | 2006-07-18 | Sanofi-Aventis Deutschland Gmbh | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use |
| US7223796B2 (en) | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
| US7049341B2 (en) | 2002-06-07 | 2006-05-23 | Aventis Pharma Deutschland Gmbh | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| US7262220B2 (en) | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
| MXPA05000053A (es) | 2002-07-12 | 2005-04-08 | Aventis Pharma Gmbh | Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos. |
| US20040157922A1 (en) | 2002-10-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments |
| US7208504B2 (en) | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| US20040242583A1 (en) | 2003-01-20 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use |
| US7179941B2 (en) | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7196114B2 (en) | 2003-02-17 | 2007-03-27 | Sanofi-Aventis Deutschland Gmbh | Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use |
| DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308352A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308351A1 (de) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
| DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
| DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
| CA2530634A1 (en) * | 2003-06-12 | 2004-12-23 | Menachem Rubinstein | Methods of treating obesity and related disorders using tellurium and selenium compounds |
| US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
| US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
| US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
| DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
| US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
| US7498341B2 (en) | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| US7402674B2 (en) | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
| JP2008517976A (ja) | 2004-10-25 | 2008-05-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物 |
| DE102004059470A1 (de) | 2004-12-10 | 2006-06-14 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von Carbaminsäureester-Derivaten |
| US20090082435A1 (en) * | 2005-04-28 | 2009-03-26 | The Regents Of The University Of California | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders |
| DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP1951688A1 (en) | 2005-10-25 | 2008-08-06 | Council of Scientific and Industrial Research | A novel compound, useful for pancreatic lipase inhibition and the process for isolation thereof |
| CN101443314B (zh) | 2006-03-13 | 2014-04-09 | 杏林制药株式会社 | 作为gsk-3抑制剂的氨基喹诺酮类 |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| NZ574710A (en) | 2006-09-07 | 2012-02-24 | Nycomed Gmbh | Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus |
| DE102007002260A1 (de) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
| DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
| CA2690004C (en) | 2007-06-04 | 2018-01-23 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
| JP5426552B2 (ja) | 2007-09-11 | 2014-02-26 | 杏林製薬株式会社 | Ｇｓｋ−３阻害剤としてのシアノアミノキノロン及びテトラゾロアミノキノロン |
| MX2010002662A (es) | 2007-09-12 | 2010-04-09 | Activx Biosciences Inc | Aminoquinolonas espirociclicas como inhibidores de gsk-3. |
| DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
| DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| JP2010254623A (ja) * | 2009-04-24 | 2010-11-11 | Takeda Chem Ind Ltd | ベンゾオキサジノン化合物の結晶 |
| CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
| WO2011039338A2 (en) | 2009-10-02 | 2011-04-07 | Sanofi-Aventis | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
| MX336966B (es) * | 2011-01-13 | 2016-02-08 | Novartis Ag | Novedosos derivados y su uso en el tratamiento de transtornos neurologicos. |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| KR20160094956A (ko) | 2013-11-05 | 2016-08-10 | 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 | 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물 |
| CN104374836A (zh) * | 2014-09-19 | 2015-02-25 | 安徽安科生物工程（集团）股份有限公司 | 西替利司他及有关杂质的hplc测定方法 |
| CN105622539B (zh) * | 2016-03-11 | 2016-11-23 | 中山万汉医药科技有限公司 | 一种西替利司他的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3450700A (en) * | 1966-12-20 | 1969-06-17 | Upjohn Co | 2-tertiary amino-4h-3,1-benzoxazin-4-ones |
| DE2315303A1 (de) * | 1973-03-27 | 1974-10-17 | Bayer Ag | Verfahren zur herstellung von n-substituierten 2-amino-3,1-benzoxazin-4-onen |
| NZ210669A (en) * | 1983-12-27 | 1988-05-30 | Syntex Inc | Benzoxazin-4-one derivatives and pharmaceutical compositions |
| US4657893A (en) * | 1984-05-09 | 1987-04-14 | Syntex (U.S.A.) Inc. | 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors |
| US4665070A (en) | 1985-06-25 | 1987-05-12 | Syntex (U.S.A.) Inc. | 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use |
| US4745116A (en) | 1985-06-25 | 1988-05-17 | Syntex (U.S.A.) Inc. | 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use |
| US5652237A (en) * | 1994-09-09 | 1997-07-29 | Warner-Lambert Company | 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes |
| US5985872A (en) * | 1995-05-24 | 1999-11-16 | G.D. Searle & Co. | 2-amino-benzoxazinones for the treatment of viral infections |
| US5776756A (en) * | 1995-08-31 | 1998-07-07 | Toyo Hakko Co., Ltd. | Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity |
| GB9900416D0 (en) * | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
-
1999
- 1999-01-08 GB GBGB9900416.0A patent/GB9900416D0/en not_active Ceased
-
2000
- 2000-01-05 AR ARP000100028A patent/AR022203A1/es active IP Right Grant
- 2000-01-06 JP JP2000592277A patent/JP2002534419A/ja not_active Withdrawn
- 2000-01-06 AT AT00900081T patent/ATE293610T1/de not_active IP Right Cessation
- 2000-01-06 AU AU18845/00A patent/AU770342B2/en not_active Ceased
- 2000-01-06 ES ES00900081T patent/ES2240051T3/es not_active Expired - Lifetime
- 2000-01-06 PT PT00900081T patent/PT1144395E/pt unknown
- 2000-01-06 CN CNB008036217A patent/CN100480245C/zh not_active Expired - Fee Related
- 2000-01-06 MY MYPI20000045A patent/MY129247A/en unknown
- 2000-01-06 RU RU2001121983/04A patent/RU2244711C2/ru not_active IP Right Cessation
- 2000-01-06 CA CA002359987A patent/CA2359987C/en not_active Expired - Fee Related
- 2000-01-06 HU HU0104909A patent/HUP0104909A3/hu unknown
- 2000-01-06 EP EP00900081A patent/EP1144395B1/en not_active Expired - Lifetime
- 2000-01-06 KR KR1020017008596A patent/KR100615914B1/ko not_active IP Right Cessation
- 2000-01-06 PL PL00350412A patent/PL350412A1/xx not_active Application Discontinuation
- 2000-01-06 NZ NZ512739A patent/NZ512739A/en not_active IP Right Cessation
- 2000-01-06 DE DE60019556T patent/DE60019556T2/de not_active Expired - Lifetime
- 2000-01-06 DK DK00900081T patent/DK1144395T3/da active
- 2000-01-06 WO PCT/GB2000/000031 patent/WO2000040569A1/en active Search and Examination
-
2001
- 2001-07-06 NO NO20013380A patent/NO321058B1/no not_active IP Right Cessation
- 2001-07-06 US US09/901,868 patent/US6656934B2/en not_active Expired - Fee Related
-
2002
- 2002-11-27 US US10/306,375 patent/US7776853B2/en not_active Expired - Fee Related
- 2002-12-12 HK HK02109007.0A patent/HK1047284A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO321058B1 (no) | Anvendelse av 2-aminobenzoksazinonderivater ved fremstilling av et medikament for profylakse eller behandling av overvekt eller en overvektsrelatert forstyrrelse, 2-aminobenzoksazinonderivater, fremgangsmate for fremstilling derav, farmasoytiske preparater og matprodukter som inneholder derivatene, anvendelser av derivatene samt kosmetisk fremgangsmate ved administrering derav. | |
| AU765147C (en) | 2-Oxy-4H-3,1-Benzoxazin-4-Ones for the treatment of obesity | |
| EP1255742B1 (en) | 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors | |
| US20090029978A1 (en) | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | |
| AU2002321536A1 (en) | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |